Europeanhhm

Siemens Healthineers Introduces Atellica CI Analyzer, a Compact Testing System to Tackle Laboratory Challenges

Friday, July 21, 2023

Siemens Healthineers has expanded its Atellica in vitro diagnostics portfolio with the Atellica CI Analyzer, a state-of-the-art solution for immunoassay and clinical chemistry testing. The analyzer has received FDA clearance and is now available in numerous major markets worldwide, offering competitive advantages to labs operating at low to medium testing volumes.

Irrespective of their size, every laboratory faces significant challenges due to labor shortages, such as producing reliable test results, ensuring staff safety, securing data, and meeting environmental goals. The Atellica CI Analyzer addresses these challenges, providing both standalone labs and satellite labs within wider health networks access to the same reagents, consumables, and intelligent software as the company's flagship Atellica Solution. Its compact 1.9 square meters footprint makes it particularly suitable for smaller laboratories.

Sharon Bracken, head of Diagnostics for Siemens Healthineers, underscores theimportance of workflow standardization and clinical equivalence for successful laboratory operations within health networks. The Atellica CI Analyzer elevates laboratory operations to a new level of agility, proactively anticipating workflow bottlenecks and providing insights based on data to enhance the efficiency of laboratory staff.

Dr. Mustafa Serteser, CEO of Acibadem Labmed Clinic Laboratories and a Siemens Healthineers customer, praises the Atellica CI Analyzer as a best-in-class approach for mid- or low-volume sized laboratories. The analyzer's thoughtful engineering includes differentiating capabilities that optimize lab efficiency and profitability, leveraging downtime effectively.

The Atellica CI Analyzer is designed with advanced features like random access sampling, micro-volume aspiration, and automatic maintenance and quality control scheduling. These capabilities enable labs to deliver more predictable sample turnaround times, with its chemistry and immunoassay engines running independently to ensure uninterrupted throughput.

In addition to delivering patient results, the Atellica CI Analyzer addresses reporting requirements, cybersecurity, and staff satisfaction goals. Equipped with the Atellica Laboratory Evaluation Suite, it provides inspection-ready reports, helping labs meet accreditation guidelines without the need for additional software, and allowing laboratory staff to focus on other critical lab operations. The system also offers user authentication, role-based authorizations, and audit trails for enhanced security.

With a planned menu of over 200 assays covering 20 disease states, each lab in a health network can select the most suitable tests for its patient population, meeting clinical needs and keeping pace with increasing demand. Moreover, more than 50 key assays can deliver results in under 14 minutes, ensuring efficient and timely diagnostics. The Atellica CI Analyzer aims to revolutionize laboratory capabilities, optimizing performance, and delivering improved patient care outcomes.

https://www.businesswire.com/news/home/20230720998119/en/


 

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CNO SummitHealthcare CMO Summit